Zelira Therapeutics (AU:ZLD)
ASX:ZLD
Want to see AU:ZLD full AI Analyst Report?
ZLD Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$1.15
Previous CloseN/A
Volume190.00
Average Volume (3M)1.92K
Market Cap
AU$5.95M
Enterprise ValueAU$8.08M
Total Cash (Recent Filing)AU$5.66K
Total Debt (Recent Filing)AU$2.14M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Monetization Model (products + B2B Licensing)A dual monetization model (consumer product commercialization plus licensing/co-development) provides structurally different revenue levers. Over 2-6 months this can reduce single-channel risk, allow scalable IP-based revenue with limited incremental capex, and support sustained upside if partnerships progress.
Proprietary Cannabinoid R&D And Commercialization ExperienceOwning formulations and development expertise in cannabinoid therapeutics creates a durable competitive asset: proprietary IP and formulation know-how align with expanding medicinal-cannabis markets and allow recurring licensing, product rollouts, and differentiation versus generic suppliers over the medium term.
Lean Operating Base And Improving Free Cash Flow TrendA very small headcount and an observed uptick in free cash flow growth imply lower fixed overhead and potential runway benefits. Lean operations can extend survival while the company pursues licensing or targeted commercialization, supporting structural resilience during a multi-quarter recovery.
Bears Say
Severe Revenue CollapseA nearly complete revenue collapse is a persistent structural concern: it erodes market foothold, limits internal funding for R&D and commercialization, and increases reliance on external financing or deals. Recovering meaningful sales will likely take multiple quarters and partners.
Negative Gross, Operating And Net MarginsSustained negative margins indicate the business is not yet converting R&D and commercialization efforts into profitable sales. Over the medium term, persistent margin deficits constrain reinvestment, pressure cash reserves, and make the company dependent on financing or material strategic partnerships to scale.
Balance-sheet Instability And Negative Cash FlowsNegative equity and ongoing negative operating cash flow are structural risks that reduce financial flexibility. They limit the firm's ability to fund development internally, raise debt on favorable terms, and increase dilution or refinancing risk, creating a multi-quarter headwind to executing strategy.
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.31 and its highest was AU$1.15 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is AU$5.95M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 89 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics (ZLD) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapeutics. Operating primarily in the healthcare sector, Zelira aims to address various health conditions, including chronic pain, sleep disorders, and other serious ailments. The company leverages its proprietary formulations and clinical research to create products that are designed to improve patient outcomes and quality of life.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―